KenvueKVUEEarnings & Financial Report
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
KVUE Q1 FY2027 Key Financial Metrics
Revenue
$3.9B
Gross Profit
$2.3B
Operating Profit
$767.0M
Net Profit
$474.0M
Gross Margin
58.9%
Operating Margin
19.6%
Net Margin
12.1%
YoY Growth
4.5%
EPS
$0.25
Kenvue Q1 FY2027 Financial Summary
Kenvue reported revenue of $3.9B (up 4.5% YoY) for Q1 FY2027, with a net profit of $474.0M (up 47.2% YoY) (12.1% margin). Cost of goods sold was $1.6B, operating expenses totaled $1.5B.
Key Financial Metrics
| Total Revenue | $3.9B |
|---|---|
| Net Profit | $474.0M |
| Gross Margin | 58.9% |
| Operating Margin | 19.6% |
| Report Period | Q1 FY2027 |
Kenvue Annual Revenue by Year
Kenvue annual revenue history includes year-by-year totals (for example, 2025 revenue was $15.1B).
Kenvue Quarterly Revenue & Net Profit History
Kenvue results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2027 | $3.9B | +4.5% | $474.0M | 12.1% |
| Q4 FY2025 | $3.8B | +3.2% | $330.0M | 8.7% |
| Q3 FY2025 | $3.8B | -3.5% | $398.0M | 10.6% |
| Q2 FY2025 | $3.8B | -4.0% | $420.0M | 10.9% |
| Q1 FY2025 | $3.7B | -3.9% | $322.0M | 8.6% |
| Q4 FY2024 | $3.7B | -6.5% | $293.0M | 8.0% |
| Q3 FY2024 | $3.9B | -2.8% | $383.0M | 9.8% |
| Q2 FY2024 | $4.0B | +3.8% | $58.0M | 1.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.00B | $3.90B | $3.66B | $3.74B | $3.84B | $3.76B | $3.78B | $3.91B |
| YoY Growth | 3.8% | -2.8% | -6.5% | -3.9% | -4.0% | -3.5% | 3.2% | 4.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.44B | $26.93B | $25.60B | $26.26B | $27.13B | $27.25B | $27.08B | N/A |
| Liabilities | $16.27B | $16.28B | $15.93B | $16.20B | $16.40B | $16.61B | $16.31B | N/A |
| Equity | $10.18B | $10.64B | $9.67B | $10.05B | $10.73B | $10.63B | $10.77B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $440.0M | $249.0M | $793.0M | $428.0M | $621.0M | $294.0M | $854.0M |